Drugs / velapatasvir
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03520660 | Oct 2018 → Dec 2032 expected | cardiovascular disorder, chronic hepatitis C virus infection, diabetes mellitus | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | velapatasvir | “sofosbuvir/velapatasvir combination (Epclusa)” NCT03520660 ↗ |
| Route | Oral | “Take 1 tablet containing 2 hepatitis C drugs once a day for 12 weeks.” NCT03520660 ↗ |